Cytokine signature in airway inflammation with arrays

Chronic Mucosal Inflammation is the hallmark of common airway diseases (ex.  Allergic Rhinitis and asthma). Lipoxin B4(LXB4) is an endogenous mucosal protective mediator decreasing such diseases. LXB4 mechanisms of action remain poorly understood.

Cytokine Quantibody Arrays from Raybiotech and tebu-bio laboratories

Cytokine Quantibody Arrays from Raybiotech and tebu-bio laboratories.

In a recent paper in Mucosal Immunology (Karra, L. et al. (2015) 8; DOI:10.1038/mi.2014.116), Allergic Rhinitis  and asthma murine models have been described to better investigate the role of LXB4 in Mucosal Inflammation. The authors conclude that, in the upper airway, LXB4 significantly decreases nasal mucosal leukocytes and degranulation of Mast Cells (MCs) and Eosinophils. They also show that, in the lower airway, LXB4 significantly decreased airway inflammation, mucus metaplasia, and hyper-responsiveness.

Inhibition of MC degranulation in vivo by LXB4 is more potent than Dexamethasone (a well-known apoptosis inducing glucocorticoid) with unique profiles for cytokine regulation. This latter  is proved by  quantitative analysis of 20 murine cytokines in a single array (Quantibody Cytokine Array).

These findings indicate that LXB4 carries cell type selective and mucosal protective actions and need to be translated to human models. This publication opens the way to consider lipoxins as new therapeutical candidates.

tebu-bio: European RaybioTech's Certified Laboratory service provider

tebu-bio laboratories are the European RaybioTech’s Certified Laboratory service provider.

The Cytokine Arrays are available as ready-to-use assays. They can also be outsourced to Certified Service Laboratory Providers as fee-for-services. In that case, researchers just send their samples and in return receive the experimental data set. To ensure top quality in the data obtained, Raybiotech’s service providers successfully complete training and certification programs to receive the “RayBiotech Certified Array Service Providers” yellow award.

In Europe, tebu-bio laboratories (France) were among the first laboratories in the world to be certified by Raybiotech in 2012. tebu-bio’s services also cover Quansys BioSciences and FullMoon BioSystems technologies for outsourcing protein profiling and quantification.

IL-1 family quantified simultaneously…at last!

The IL-1 family has long been known as a key player in the effector role of macrophages in innate defence against tumours and infections. It plays an important role in the field of natural / innate immunity effector mechanisms, especially as far as macrophage and macrophage-derived cytokines are concerned, in defence response. It also seems to be involved in pregnancy and pre-eclampsia (1), as well as cardiovascular diseases and type 2 diabetes (2). It is also involved in the response to Carbon Nanotubes (CNTs) exposure, where IL-1 family members activate the JNK pathway, but not ERK (3). [Read more…]

It’s not always lupus

Fans of the series Dr. House know that in most episodes, lupus is one of the diseases considered as a tentative diagnosis by Dr. House’s team. In fact, it’s quite nice when you see how they go to the laboratory and try to check whether this possibility is true or not by looking at different biomarkers. Even TV series show the need for accurate biomarkers allowing to make an early diagnosis. [Read more…]

Immunotherapy Screening – B7-1 / CD28 and B7-1 / CTLA4 Pathways in Drug Discovery

The treatment of diseases by inducing, enhancing, or surpressing an immune response is referred to as Immunotherapy. T-cell activation and inactivation requires the coordination of various co-inhibitory and co-stimulatory signals and most immunotherapies modulate these signals.

Therapeutic manipulation of immunopathways has lead to promising clinical results for the treatment of a number of diseases such as cancer, autoimmune diseases and inflammatory diseases. Research in this field is rapidly evolving as scientists seek to identify the next generation of therapies.

In the first post of a series of three,  I will describe the B7-1 : CD28 and B7-1 : CTLA4 pathways and summarize the portfolio of tools currently available to researchers to investigate these pathways. In fact, these are the first kits on the market to screen for inhibitors of these pathways. [Read more…]

Innovation in Life Sciences: Bead Arrays for Antibody and Complement Profiling by Ayogly et al.

Ayogly et al. have designed an innovative suspension bead-array experimental approach for studying in one assay both antigen-specific antibody reactivity and complement activation induced C3 deposition.

The benefits of such a scalable approach is based on its capacity to measure multiplex antigen-specific complement activation in the context of an autoimmune disease (ex. Rheumatoid Arthritis) and viral antigen detection (ex. Epstein-Barr virus encoded Nuclear Antigen-1 (EBNA-1)).

The combination of antibody reactivity profiling and induced complement activation in one assay open new perspectives in autoantibody- and virus-induced immune diseases.

Want to know more?

Ayoglu B. et al. “Bead Arrays for Antibody and Complement Profiling Reveal Joint Contribution of Antibody Isotypes to C3 Deposition (5 May, 2014) PLoS ONE, CrossRef DOI Link to Publisher-Maintained copy: http://dx.doi.org/10.1371/journal.pone.0096403

Congratulations to the authors, who turned to tebu-bio’s range of products when selecting their antigens (ex. EBNA-1 protein) coupled to beads to determine the optimal assay conditions for measuring complement activation.